



**“onestopshop”
B2B woundcare solutions**

Priyanka Dutta Passecker, MBA, Ph.D.
CEO & co-founder

Company Mission and milestones



We have a mission

to heal life, by leveraging **best-in-class swiss innovation** including enzyme technologies, stem cells, and natural molecules to deliver personalised, and precision medicine. There remains a major gap in the current treatment paradigm. **No permanent therapy for non-healing wounds** currently exists.

Product Pipeline

-  **2023**
Cell Therapy – *Epidex*
Epidermal skin patch
-  **2025**
Wound Debrider – *AQUAtryp*
-  **2026**
Medical Device – Blood patch
-  **2027**
Cell Therapy – *Allogenic cell therapy*

No satisfactory therapy for hard-to-heal wounds currently exists...

There are **60M** chronic wound patients worldwide:

- 2-3% of the elderly have painful Venous/Arterial Leg Ulcers
- 25% of diabetics have disabling diabetic foot ulcers




Today it is


- Not personalized
- Not affordable
- Not efficient

≈ **60%** of chronic wounds remain unhealed

healiva® portfolio addresses the entire spectrum of the wound-care process for chronic wounds, from key first steps to the completion of closure



healiva® technological breakthroughs



The opportunity is vast with >16B CHF of potential revenue

1-2%

of the population will suffer from a chronic wound within their lifetime

3 to 4


persons per 1,000 people prevalence of wounds in the EU ²

9.7 M

Venous ulcers in the world

10 M

Diabetic ulcers in the world



Now is the time to bring cell therapies in wound care to the market

The use of cell therapy for wound care has been in development for over 20 years, but the market viability of cell therapy has been limited – *until now* – for a number of reasons...

- **Scalability and cost** – Previously, manufacturing would have required company-owned factories for production. Now, contract manufacturing is widely available, enabling increased scalability on a flexible basis. This reduces manufacturing costs, enables affordable market pricing, and provides a good profit margin.
- **Regulatory preparedness** – regulatory bodies are now experienced and prepared to approve cell therapies for market indications.
- **Product safety and public perception** – the science and safety behind the technology is now well researched and better understood, providing greater public acceptance of the concept.

Join us in personalizing wound care treatment

Partnership/ Members



Farma Industria Ticino
since 1980



Swiss Healthcare Startups

Healiva® Acquires Critical Cell Therapy Manufacturing Assets From B. Braun



The acquisition will accelerate the launch of Healiva's personalised skin regeneration therapy, EpiDex®

November 21, 2022 08:00 AM Eastern Standard Time

BioWorld™

Healiva® Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew

FINANCIAL TIMES

Healiva to resurrect wound care cell therapies after Smith & Nephew asset acquisition

By Cormac Sheridan June 1, 2022



Boldbrain
STARTUP CHALLENGE